19 102 patients, 51 countries, 1139 centers Fox K, Ford I, Steg PG, Tardif JC, Tendera M, Ferrari R. Rationale, design, and baseline characteristics of.

Slides:

Advertisements

Similar presentations

Pexelizumab for the Reduction of Infarction and Mortality in Coronary Artery Bypass Graft ll (PRIMO-CABG II) Trial Presented at The American College of.

Advertisements

ONgoing Telmisartan Alone and in combination with Ramipril Global Endpoint Trial The telmisartan trial in cardiovascular protection Sponsored by Boehringer.

Effects of selective heart rate reduction with ivabradine on left ventricular remodelling and function: results from the SHIFT echocardiography substudy.

K Fox, W Remme, C Daly, M Bertrand, R Ferrari, M Simoons On behalf of the EUROPA investigators. The diabetic sub study of.

Trial profile Fox K et al. Lancet 2008;372:

TNT: Study Design Treating to New Targets 2 5 years 10,001 Patients Clinically evident CHD LDL-C 130  250 mg/dL following up to 8-week washout and 8-week.

FAME 2 year Objective:To investigate the 2-year outcome of PCI guided by FFR in patients with multivessel CAD. Study:Multicenter, single blind, randomized.

S ystolic H eart failure treatment with the I f inhibitor ivabradine T rial Heart rate reduction with ivabradine and health related quality of life in.

analysis from the SHIFT study

Results Fox K, Ford I, Steg PG, Tardif JC, Tendera M, Ferrari R. N Eng J Med August 31. DOI: /NEJMoa

May 23rd, 2012 Hot topics from the Heart Failure Congress in Belgrade.

COURAGE: Clinical Outcomes Utilizing Revascularization and Aggressive Drug Evaluation Purpose To compare the efficacy of optimal medical therapy (OMT)

CHARM-Alternative: Candesartan in Heart failure: Assessment of Reduction in Mortality and morbidity - Alternative Purpose To determine whether the angiotensin.

CHARM-Preserved: Candesartan in Heart failure: Assessment of Reduction in Mortality and morbidity - Preserved Purpose To determine whether the angiotensin.

Effects on outcomes of heart rate reduction by ivabradine in patients with congestive heart failure: is there an influence of beta-blocker dose? Systolic.

Effect of ivabradine on recurrent hospitalization for worsening heart failure: findings from SHIFT S ystolic H eart failure treatment with the I f inhibitor.

BEAUTI f UL: morBidity-mortality EvAlUaTion of the I f inhibitor ivabradine in patients with coronary disease and left ventricULar dysfunction Purpose.

Clinical implications. Burden of coronary disease 56 millions deaths worldwide in millions deaths worldwide in % due to CV disease (~ 16.

Clinical Outcomes with Newer Antihyperglycemic Agents

Design and baseline characteristics. Trial hypothesis Fox K et al. Am Heart J. 2013;166(4): SIGNIFY is assessing whether heart rate reduction.

Fenofibrate Intervention and Event Lowering in Diabetes FIELDFIELD Presented at The American Heart Association Scientific Sessions, November 2005 Presented.

Effect of ivabradine on recurrent hospitalization for worsening heart failure: findings from SHIFT S ystolic H eart failure treatment with the I f inhibitor.

BARI 2D Trial BARI 2D Trial Presented at the American Diabetes Association (ADA) Annual Scientific Sessions 2009 in New Orleans The Bypass Angioplasty.

A step further in the management of stable coronary patients with ivabradine.

Copyleft Clinical Trial Results. You Must Redistribute Slides HYVET Trial The Hypertension in the Very Elderly Trial (HYVET)

S ystolic H eart failure treatment with the I f inhibitor ivabradine T rial Efficacy and safety of ivabradine in patients with severe chronic systolic.

Aim To determine the effects of a Coversyl- based blood pressure lowering regimen on the risk of recurrent stroke among patients with a history of stroke.

WOSCOPS: West Of Scotland Coronary Prevention Study Purpose To determine whether pravastatin reduces combined incidence of nonfatal MI and death due to.

Lancet 373: , 2009 Baseline Characteristics of Participants and Study Design of Clinical Trials to Compare Intensive glucose- lowering versus.

The effect of heart rate reduction with ivabradine on renal function in patients with chronic heart failure: an analysis from SHIFT Systolic Heart failure.

CIBIS II Cardiac Insufficiency Bisoprolol Study

ACCP Cardiology PRN Journal Club

Heart rate in heart failure: Heart rate in heart failure: risk marker or risk factor? A subanalysis of the SHIFT trial on behalf of the Investigators M.

Prevention of Events with Angiotensin Converting Enzyme Inhibition (PEACE) Trial PEACE Trial Presented at The American Heart Association Scientific Sessions.

4S: Scandinavian Simvastatin Survival Study

Bangalore S, et al. β-Blocker use and clinical outcomes in stable outpatients with and without coronary artery disease. JAMA. 2012;308(13): ?

Perindopril Remodeling in Elderly with Acute Myocardial Infarction PREAMIPREAMI Presented at The European Society of Cardiology Hot Line Session, September.

? What more will it take to turn the tide of treatment for angina patients from a PCI-first to an optimal medical therapy– first approach? 1.

STICH CABG Objective To determine whether surgery plus medical management or medical management alone improve outcomes in CABG patients Study Design 1212.

Ischemia Management with Accupril Post Bypass Graft via Inhibition of Angiotensin Converting Enzyme IMAGINEIMAGINE Presented at The European Society of.

New 2011 SHIFT quality of life substudy Quality of life ( QoL) in heart failure: where do we stand? Therapies that have survival benefits either have a.

European trial on reduction of cardiac events with perindopril in stable coronary artery disease Presented at European Society of Cardiology 2003 EUROPA.

The JUPITER Trial Reference Ridker PM. Rosuvastatin to prevent vascular events in men and women with elevated C-reactive protein. N Engl J Med. 2008;359:2195–2207.

Ten Year Outcome of Coronary Artery Bypass Graft Surgery Versus Medical Therapy in Patients with Ischemic Cardiomyopathy Results of the Surgical Treatment.

Angela Aziz Donnelly April 5, 2016

Cardiovascular Disease and Antihypertensives The RENAAL Trial Reference Brunner BM, and the RENAAL study group. Effects of losartan on renal and cardiovascular.

An analysis of 22,672 patients from the CLARIFY registry

HOPE: Heart Outcomes Prevention Evaluation study

REVEAL: Randomized placebo-controlled trial of anacetrapib in 30,449 patients with atherosclerotic vascular disease Louise Bowman on behalf of the HPS.

Heart Rate, Life Expectancy and the Cardiovascular System: Therapeutic Considerations Cardiology 2015;132: DOI: / Fig. 1. Semilogarithmic.

AIM HIGH Niacin plus Statin to prevent vascular events

CANTOS: The Canakinumab Anti-Inflammatory Thrombosis Outcomes Study

Scandinavian Simvastatin Survival Study (4S)

FATS- Familial Atherosclerosis Treatment Study

Avoiding Cardiovascular events through COMbination therapy in Patients LIving with Systolic Hypertension (ACCOMPLISH): Design Randomized, double-blind.

The following slides highlight a report on a presentation at the Late-breaking Trials Session and a Satellite Symposium of the American Heart Association.

Systolic Heart failure treatment with the If inhibitor ivabradine Trial The effect of heart rate reduction with ivabradine on renal function in patients.

Baseline characteristics of patients

The Hypertension in the Very Elderly Trial (HYVET)

SIGNIFY Trial design: Participants with stable coronary artery disease without clinical heart failure and resting heart rate >70 bpm were randomized to.

Using Heart Rate as a Biomarker in Clinical Practice.

Exercise-Based Cardiac Rehabilitation and Improvements in Cardiorespiratory Fitness: Implications Regarding Patient Benefit Barry A. Franklin, PhD Mayo.

American Heart Association Presented by Dr. Julinda Mehilli

LRC-CPPT and MRFIT Content Points:

ARISE Trial Aggressive Reduction of Inflammation Stops Events

Inclusion Criteria for Patients with Multiple Atherothrombotic Risk Factors and for Those with Established Cardiovascular Disease Deepak L.Bhatt, et al,

Systolic Heart failure treatment with the If inhibitor ivabradine Trial Effect of ivabradine on recurrent hospitalization for worsening heart failure:

These slides highlight a report from a Hotline Session and a Satellite symposium held at the European Society of Cardiology Congress, 2003 in Vienna Austria,

The Heart Rhythm Society Meeting Presented by Dr. Johan De Sutter

Pamela E. Scott et al. JACC 2018;71:

Presentation transcript:

patients, 51 countries, 1139 centers Fox K, Ford I, Steg PG, Tardif JC, Tendera M, Ferrari R. Rationale, design, and baseline characteristics of the Study assessInG the morbidity-mortality beNefits of the I f inhibitor ivabradine in patients with coronarY artery disease (SIGNIFY trial): A randomized, double-blind, placebo-controlled trial of ivabradine in patients with stable coronary artery disease without clinical heart failure. Am Heart J. 2013;166: The SIGNIFY study

Study design Mean follow-up of 2.75 years Fox K, Ford I, Steg PG, Tardif JC, Tendera M, Ferrari R. Rationale, design, and baseline characteristics of the Study assessInG the morbidity-mortality beNefits of the I f inhibitor ivabradine in patients with coronarY artery disease (SIGNIFY trial): A randomized, double-blind, placebo-controlled trial of ivabradine in patients with stable coronary artery disease without clinical heart failure. Am Heart J. 2013;166:

Study population Proven stable CAD Proven stable CAD Age >55 years Age >55 years Without LVSD (EF >40%, no clinical signs of HF) Without LVSD (EF >40%, no clinical signs of HF) In sinus rhythm, with a resting heart rate >70 bpm In sinus rhythm, with a resting heart rate >70 bpm Receiving appropriate stable conventional cardiovascular medication Receiving appropriate stable conventional cardiovascular medication With one or more other cardiovascular risk factors With one or more other cardiovascular risk factors Fox K, Ford I, Steg PG, Tardif JC, Tendera M, Ferrari R. Rationale, design, and baseline characteristics of the Study assessInG the morbidity-mortality beNefits of the I f inhibitor ivabradine in patients with coronarY artery disease (SIGNIFY trial): A randomized, double-blind, placebo-controlled trial of ivabradine in patients with stable coronary artery disease without clinical heart failure. Am Heart J. 2013;166:

Study end points Cardiovascular death or nonfatal myocardial infarction Primary composite end point Secondary end points All-cause death Cardiovascular death Coronary death Nonfatal myocardial infarction Coronary revascularization Elective coronary revascularization New-onset or worsening heart failure Fox K, Ford I, Steg PG, Tardif JC, Tendera M, Ferrari R. Rationale, design, and baseline characteristics of the Study assessInG the morbidity-mortality beNefits of the I f inhibitor ivabradine in patients with coronarY artery disease (SIGNIFY trial): A randomized, double-blind, placebo-controlled trial of ivabradine in patients with stable coronary artery disease without clinical heart failure. Am Heart J. 2013;166:

Baseline characteristics Whole population (N = ) Demographic characteristics Age (y) < Body mass index (kg/m 2 ) Heart rate (beats/min) Male Ethnic origin White Asian Other Systolic blood pressure (mm Hg) Diastolic blood pressure (mm Hg) CAD duration (y) 65.0 ± (72) 5433 (28) 2227 (12) 28.8 ± ± (72) (81) 2547 (13) 1022 (5) ± ± ± 6.3 Values are means SD or n (%).

Fox K, Ford I, Steg PG, Tardif JC, Tendera M, Ferrari R. Rationale, design, and baseline characteristics of the Study assessInG the morbidity-mortality beNefits of the I f inhibitor ivabradine in patients with coronarY artery disease (SIGNIFY trial): A randomized, double-blind, placebo-controlled trial of ivabradine in patients with stable coronary artery disease without clinical heart failure. Am Heart J. 2013;166: Baseline characteristics

Fox K, Ford I, Steg PG, Tardif JC, Tendera M, Ferrari R. Rationale, design, and baseline characteristics of the Study assessInG the morbidity-mortality beNefits of the I f inhibitor ivabradine in patients with coronarY artery disease (SIGNIFY trial): A randomized, double-blind, placebo-controlled trial of ivabradine in patients with stable coronary artery disease without clinical heart failure. Am Heart J. 2013;166: Baseline characteristics

Planned substudies Fox K, Ford I, Steg PG, Tardif JC, Tendera M, Ferrari R. Rationale, design, and baseline characteristics of the Study assessInG the morbidity-mortality beNefits of the I f inhibitor ivabradine in patients with coronarY artery disease (SIGNIFY trial): A randomized, double-blind, placebo-controlled trial of ivabradine in patients with stable coronary artery disease without clinical heart failure. Am Heart J. 2013;166: The Quality of Life Substudy is designed to evaluate changes in the Seattle Angina Questionnaire in 4500 patients with angina pectoris at baseline (CCS class II or higher), depending on the availability of an approved translation of the questionnaire. The aim of the Biomarkers Substudy is to detect changes in circulating von Willebrand factor, as well as high-sensitivity troponin T and other biomarkers of CAD progression and endothelial function, in a group of 380 patients at baseline and at 3 and 12 months, in centers that meet the technical requirements. The Pharmacogenomics Substudy will analyze whether genetic variations in candidate genes and in the whole genome are associated with clinical outcomes in about 5000 patients in countries where such studies receive ethical/regulatory approval.

Official study website Read more about SIGNIFY at